Introduction
============

Head and neck squamous cell carcinoma (HNSCC) occurs from the mucosa in the upper aerodigestive tract, including the oral cavity, oropharynx, hypopharynx and larynx, and this disease is the sixth most common cancer worldwide ([@b1-ijo-52-01-0166]). Approximately 550,000 new patients are diagnosed, and 30,000 patients die of this disease annually ([@b2-ijo-52-01-0166]). Due to the local recurrence and distant metastasis of HNSCC, the overall survival of patients with HNSCC has not improved in the last decade ([@b3-ijo-52-01-0166]). Currently developed targeted molecular therapies are not sufficiently efficacious in the management of HNSCC ([@b3-ijo-52-01-0166]). Therefore, improving our understanding of the molecular mechanisms of HNSCC aggressiveness is needed based on current genomic approaches.

MicroRNAs (miRNAs) are small noncoding RNAs (19--22 nucleotides in length) involved in the repression or degradation of target RNA transcripts in a sequence-dependent manner ([@b4-ijo-52-01-0166]). One of the unique features of miRNAs is that a single miRNA regulates a vast number of protein-coding or noncoding RNAs in human cells ([@b5-ijo-52-01-0166]). Thus, aberrant expression of miRNAs disrupts systematically regulated RNA networks in cancer cells. In fact, accumulating evidence has revealed that aberrant expression of miRNAs is deeply involved in the pathogenesis of human cancers ([@b6-ijo-52-01-0166]).

In miRNA biogenesis, precursor miRNA (pre-miRNA) is cleaved in the cytoplasm, generating a miRNA duplex comprised of a guide strand and passenger strand. The guide strand of miRNA is thought to be incorporated into the RNA-induced silencing complex (RISC) to target mRNAs, whereas the passenger strand of miRNA is degraded and is not thought to have regulatory activity in cells ([@b7-ijo-52-01-0166]). However, in contrast to this paradigm, we demonstrated that passenger strands of miRNAs, i.e., *miR-144-5p*, *miR-139-3p*, *miR-150-3p* and *miR-145-3p*, were downregulated and acted as antitumor miRNAs in several types of cancers ([@b8-ijo-52-01-0166]--[@b13-ijo-52-01-0166]). Moreover, dual strands of pre-*miR-145* (*miR-145-5p* and *miR-145-3p*) coordinately target oncogenic *MTDH* and *UHRF1* in lung cancer and bladder cancer, respectively ([@b10-ijo-52-01-0166],[@b11-ijo-52-01-0166]). The involvement of passenger miRNA strands and regulation of cancer networks by passenger miRNAs are novel concepts in cancer research.

Analysis of the miRNA expression signature of HNSCC by RNA sequencing revealed that *miR-145-5p* and *miR-145-3p* were significantly downregulated in cancer tissues. The guide strand *miR-145-5p* has been established as an oncogene in several cancers, including HNSCC ([@b14-ijo-52-01-0166]). However, the functional significance of the passenger strand of *miR-145* in HNSCC is still unknown. The aims of this present study were to investigate the antitumor function of *miR-145-3p* and to identify its target oncogenic genes in HNSCC cells. Elucidation of the antitumor roles of passenger strands of miRNAs and the cancer networks mediated by these miRNAs may provide insights into the molecular pathogenesis of HNSCC.

Materials and methods
=====================

Clinical HNSCC specimens, cell lines, and cell culture
------------------------------------------------------

A total of 22 clinical tissue specimens were collected from patients with HNSCC who underwent surgical resection at Chiba university Hospital between 2008 and 2014. The clinicopathological features of patients with HNSCC are summarized in [Table I](#tI-ijo-52-01-0166){ref-type="table"}. All patients in this study provided informed consent, and the study protocol was approved by the Institutional Review Board of Chiba University. TNM classification and tumor stage were determined by the union for International Cancer Control (UICC) ([@b15-ijo-52-01-0166]).

In this study, we used the following human HNSCC cells: SAS (derived from a primary lesion of tongue squamous cell carcinoma) and HSC3 (derived from human lymph node metastasis of tongue squamous cell carcinoma), as described previously.

Mature miRNA and small interfering RNA (siRNA) transfection into HNSCC cells
----------------------------------------------------------------------------

The following RNA species were used in this study: mature miRNAs, Pre-miR miRNA Precursors (*hsa-miR-145-3p*, assay ID: PM 13036; *hsa-miR-145-5p*, assay ID: PM 11480), negative control miRNA (assay ID: AM 17111) (both from Applied Biosystems, Foster City, CA, USA), siRNA (Stealth Select RNAi siRNA; si-*MYO1B* P/N: HSS106714 and HSS106716; Invitrogen, Carlsbad, CA, USA). The transfection procedures were described previously ([@b16-ijo-52-01-0166]--[@b20-ijo-52-01-0166]).

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)
--------------------------------------------------------------------------------

The procedure for PCR quantification was described previously ([@b16-ijo-52-01-0166]--[@b19-ijo-52-01-0166]). TaqMan probes and primers for *MYO1B* (P/N: Hs00362654_m1; Applied Biosystems) were assay-on-demand gene expression products. Expression for *miR-145-3p* (P/N: 002149; Applied Biosystems) and *miR-145-5p* (P/N: 002278) was used to quantify the expression levels of miRNAs according to the manufacturer\'s protocol. To normalize the data for quantification of mRNA and miRNAs, we used human *GUSB* (P/N: Hs99999908_m1), glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) (P/N: Hs02758991_m1) and *RNU48* (assay ID: 001006) (all from Applied Biosystems). The relative expression levels were analyzed using the 2^−ΔΔCT^ method.

Cell proliferation, migration, and invasion assays
--------------------------------------------------

Cell proliferation, migration and invasion assays were described previously ([@b16-ijo-52-01-0166]--[@b19-ijo-52-01-0166]).

Incorporation of miR-145-3p or miR-145-5p into the RISC by Ago2 immunoprecipitation
-----------------------------------------------------------------------------------

SAS cells were transfected with 10 nM miRNA by reverse transfection. After 48 h, immunoprecipitation was performed using a human Ago2 miRNA isolation kit (Wako, Osaka, Japan) according to the manufacturer\'s protocol. Expression levels of *miR-145-3p* or *miR-145-5p* were measured by qRT-PCR. miRNA data were normalized to the expression of miR-150-5p (P/N: PM10070; Applied Biosystems), which was not affected by *miR-145-3p* and *miR-145-5p* transfection.

Western blot analysis
---------------------

Cells were harvested and lysed 48 h after transfection. Each cell lysate (50 *µ*g of protein) was separated using Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA, USA) and transferred to polyvinylidene difluoride membranes. Immunoblotting was performed with monoclonal anti-*MYO1B* antibodies (1:250 dilution; HPA013607; Sigma-Aldrich, St. Louis, MO, USA). Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (1:1,000 dilution; ab8245; Abcam, Cambridge, UK) were used as an internal control. The procedures were described in our previous studies ([@b16-ijo-52-01-0166]--[@b19-ijo-52-01-0166]).

Identification of putative genes regulated by miR-145-3p in HNSCC cells
-----------------------------------------------------------------------

Specific genes regulated by *miR-145-3p* were identified by a combination of *in silico* and genome-wide gene expression analyses. Genes regulated by *miR-145-3p* were listed using the TargetScan database. Oligo microarrays (Human GE 60K; Agilent Technologies) were used for gene expression analyses. The microarray data were deposited into GEO (<http://www.ncbi.nlm.nih.gov/geo/>), with accession number GSE82108. Upregulated genes in HNSCC were obtained from publicly available data sets in GEO (accession no. GSE9638). To identify signaling pathways regulated *in silico*, gene expression data were analyzed using the KEGG pathway categories with the GeneCodis program.

Regulation of targets downstream of MYO1B in HNSCC
--------------------------------------------------

We investigated pathways regulated by *MYO1B* in HNSCC cells. We analyzed gene expression using si-*MYO1B*-transfected SAS cells. Microarray data were used for expression profiling of si-*MYO1B* transfectants. The microarray data were deposited into GEO (accession no. GSE100746). We analyzed common downregulated genes using the GEO dataset.

Plasmid construction and dual-luciferase reporter assay
-------------------------------------------------------

The partial wild-type sequence of the *MYO1B* 3′-untranslated region (3′-UTR) was inserted between the *Xho*I-*Pme*I restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). Alternatively, we used sequences that were missing the *miR-145-3p* target sites (position 88--94 or position 1117--1123). The synthesized DNA was cloned into the psiCHECK-2 vector. SAS cells were transfected with 20 ng of the vector, 20 nM microRNAs, and 1 *µ*l Lipofectamine 2000 in 100 *µ*l Opti-MEM (both from Invitrogen). The procedure of dual-luciferase reporter assay was described previously ([@b16-ijo-52-01-0166]--[@b19-ijo-52-01-0166]).

Immunohistochemistry
--------------------

Formalin-fixed, paraffin-embedded (FFPE) tissues were used. Tissue sections were incubated overnight at 4°C with anti-*MYO1B* antibodies diluted 1:300 (HPA013607; Sigma-Aldrich). The procedure for immunohistochemistry was described previously ([@b21-ijo-52-01-0166]).

The Cancer Genome Atlas (TCGA)-HNSCC data analysis
--------------------------------------------------

To explore the clinical significance of *MYO1B* in HNSCC, we used the RNA sequencing database in TCGA (<https://tcga-data.nci.nih.gov/tcga/>). The gene expression and clinical data were retrieved from cBioportal (<http://www.cbioportal.org/>, the provisional data downloaded July 1, 2017).

Statistical analysis
--------------------

Relationships between two or three variables and numerical values were analyzed using Mann-Whitney U tests or Bonferroni-adjusted Mann-Whitney U tests. Spearman\'s rank tests were used to evaluate the correlations between the expression of *miR-145-3p* or *miR-145-5p* and target genes. Expert StatView software (version 5.0; SAS Institute Inc., Cary, NC, USA) was used for these analyses. Multivariate Cox proportional hazard regression models were used to determine independent factors for survival with JMP Pro 13.

Results
=======

Expression levels of miR-145-5p and miR-145-3p in HNSCC clinical specimens and cell lines
-----------------------------------------------------------------------------------------

To confirm our miRNA expression signatures in HNSCC by RNA sequencing, we validated the expression levels of *miR-145-5p* and *miR-145-3p* in HNSCC clinical specimens and cell lines. In [Fig. 1](#f1-ijo-52-01-0166){ref-type="fig"}, the expression levels of *miR-145-5p* and *miR-145-3p* were significantly reduced in cancer tissues compared with those in corresponding adjacent noncancerous epithelium (p\<0.0001) ([Fig. 1A](#f1-ijo-52-01-0166){ref-type="fig"}). Additionally, the expression levels of *miR-145-5p* and *miR-145-3p* in SAS and HSC3 cells were markedly downregulated ([Fig. 1A](#f1-ijo-52-01-0166){ref-type="fig"}).

Spearman\'s rank test showed a positive correlation between the expression levels of *miR-145-5p* and *miR-145-3p* in clinical specimens ([Fig. 1A](#f1-ijo-52-01-0166){ref-type="fig"}).

Effects of ectopic expression of miR-145-5p and miR-145-3p on cell proliferation, migration and invasion in HNSCC cell lines
----------------------------------------------------------------------------------------------------------------------------

To validate the functional roles of *miR-145-3p* and *miR-145-5p*, we carried out gain-of-function assays using miRNA transfection into two HNSCC cell lines (SAS and HSC3). XTT assays revealed that cell proliferation was significantly inhibited in *miR-145-3p* and *miR-145-5p* transfectants in comparison with mock or miR-control transfectants ([Fig. 1B](#f1-ijo-52-01-0166){ref-type="fig"}). Similarly, migration assays showed that cell migration activity was significantly inhibited in *miR-145-3p* and *miR-145-5p* transfectants in comparison with mock and miR-control transfectants ([Fig. 1C](#f1-ijo-52-01-0166){ref-type="fig"}). Matrigel invasion assays also demonstrated that cell invasion activity was significantly inhibited in *miR-145-3p* and *miR-145-5p* transfectants in comparison with mock and miR-control transfectants ([Fig. 1D](#f1-ijo-52-01-0166){ref-type="fig"}).

Incorporation of miR-145-3p into the RISC in HNSCC cells
--------------------------------------------------------

We hypothesized that the passenger strand *miR-145-3p* may be incorporated into the RISC and exert important effects in cancer cells. Accordingly, we performed immunoprecipitation with antibodies targeting Ago2, which plays an important role in the RISC. After transfection with *miR-145-3p* or *miR-145-5p*, Ago2-bound miRNAs were isolated, and qRT-PCR was carried out to determine whether *miR-145-3p* and *miR-145-5p* bound to Ago2. After transfection with *miR-145-3p* and immunoprecipitation by anti-Ago2 antibodies, *miR-145-3p* levels were significantly higher than those of mock- or miR-control-transfected cells and those of *miR-145-5p*-transfected SAS cells (p\<0.0001) ([Fig. 2A](#f2-ijo-52-01-0166){ref-type="fig"}). Similarly, after *miR-145-5p* transfection, *miR-145-5p* was detected by Ago2 immunoprecipitation (p\<0.0001) ([Fig. 2B](#f2-ijo-52-01-0166){ref-type="fig"}).

Identification of putative targets of miR-145-3p regulation in HNSCC cells
--------------------------------------------------------------------------

We performed *in silico* and gene expression analyses to identify genes targeted by *miR-145-3p* for regulation ([Fig. 3](#f3-ijo-52-01-0166){ref-type="fig"}). First, we selected putative *miR-145-3p* target genes using the TargetScan database and identified 3,164 genes. Next, we performed comprehensive gene expression analysis using *miR-145-3p* transfectants of SAS, with negative control miRNA transfectants serving as controls (accession no. GSE 82108). A total of 1,187 genes were commonly downregulated (log~2~ ratio\<0). The gene set was then analyzed with a publicly available gene expression data set in GEO (accession no. GSE9638), and genes upregulated in HNSCC were chosen (fold-change \>1.5). A total of 14 genes were identified as candidate targets of *miR-145-3p* regulation ([Table II](#tII-ijo-52-01-0166){ref-type="table"}). Next, these genes were validated with TCGA database, and we investigated the correlations between survival rates and target genes with high or low expression. In this study, 3 genes (*MYO1B*, *C16orf74* and *RBP1*) were selected as genes that affected the patient\'s overall survival ([Table II](#tII-ijo-52-01-0166){ref-type="table"} and [Fig. 4](#f4-ijo-52-01-0166){ref-type="fig"}). Among them, *MYO1B* was found to have the greatest effect on the overall survival rate (p=0.00452). In this study, we focused on *MYO1B* as a candidate target gene of *miR-145-3p* regulation and investigated the functional roles of HNSCC cells.

Direct regulation of MYO1B by miR-145-3p in HNSCC cells
-------------------------------------------------------

Next, we investigated whether the expression of *MYO1B* decreased in *miR-145-3p*-transfected HNSCC cells. *MYO1B* mRNA levels were significantly reduced by *miR-145-3p* transfection compared with the mock or miR-control transfectants ([Fig. 5A](#f5-ijo-52-01-0166){ref-type="fig"}). Furthermore, *MYO1B* protein levels were also reduced by *miR-145-3p* transfection compared with mock or miR-control transfectants ([Fig. 5B](#f5-ijo-52-01-0166){ref-type="fig"}). In contrast, *miR-145-5p* transfectants did not show altered expression of MYO1B mRNA or protein ([Fig. 5A and B](#f5-ijo-52-01-0166){ref-type="fig"}).

We then carried out luciferase reporter assays with a vector that included the 3′-UTR of *MYO1B* to confirm that *miR-145-3p* directly regulated *MYO1B* in a sequence-dependent manner. TargetScan Human database predicted that there were two binding sites for *miR-145-3p* in the 3′-UTR of *MYO1B* (positions 88--94 and 1117--1123) ([Fig. 5C](#f5-ijo-52-01-0166){ref-type="fig"}). Cotransfection with *miR-145-3p* and vectors significantly reduced luciferase activity in comparison with those in mock and miR-control transfectants in position 1117--1123 of the *MYO1B* 3′-UTR ([Fig. 5D](#f5-ijo-52-01-0166){ref-type="fig"}).

Effects of MYO1B knockdown on cell proliferation, migration, and invasion in HNSCC cell lines
---------------------------------------------------------------------------------------------

A loss-of-function assay using siRNA was performed to examine the function of *MYO1B* in HNSCC cell lines. The expression levels of *MYO1B* mRNA and protein were reduced by si-*MYO1B* in HNSCC cell lines ([Fig. 6A and B](#f6-ijo-52-01-0166){ref-type="fig"}). Furthermore, we investigated effects of *MYO1B* knockdown on cell proliferation, migration, and invasion in HNSCC cell lines. Cancer cell proliferation was significantly reduced in si-*MYO1B* transfectants in comparison with that in mock- or miR control-transfected cell lines ([Fig. 6C](#f6-ijo-52-01-0166){ref-type="fig"}). Additionally, migration activities were significantly suppressed in si-*MYO1B* transfectants in comparison with that in mock- or miR control-transfected cell lines ([Fig. 6D](#f6-ijo-52-01-0166){ref-type="fig"}). Invasion activity was also significantly inhibited in si-*MYO1B* transfectants in comparison with that in mock- or miR control-transfected cell lines ([Fig. 6E](#f6-ijo-52-01-0166){ref-type="fig"}).

Expression of MYO1B in HNSCC clinical specimens
-----------------------------------------------

Next, we investigated the mRNA expression levels of *MYO1B* in 22 HNSCC clinical specimens by qRT-PCR. *MYO1B* was significantly upregulated in HNSCC tumor tissues ([Fig. 7A](#f7-ijo-52-01-0166){ref-type="fig"}). Spearman\'s rank test showed a negative correlation between the expression of *MYO1B* and *miR-145-3p* (p=0.0025, R=−0.461) ([Fig. 7B](#f7-ijo-52-01-0166){ref-type="fig"}). Furthermore, we also examined the expression levels of *MYO1B* in HNSCC clinical specimens by immunostaining. *MYO1B* was strongly expressed in several cancer tissues ([Fig. 7C](#f7-ijo-52-01-0166){ref-type="fig"}: 1, patient no. 2; 2, no. 3; 3, no. 7 in [Table I](#tI-ijo-52-01-0166){ref-type="table"}).

Correlation between MYO1B expression and clinicopathological characteristics in prognostic prediction in HNSCC specimens
------------------------------------------------------------------------------------------------------------------------

We collected clinical data from TCGA database and analyzed clinicopathological factors and expression of *MYO1B* as a prognostic predictive factor. The multivariate cox proportional hazards model was used to validate independent predictors for overall survival, including *MYO1B* expression, clinical T stage, clinical N stage, age, sex and histologic grade. As a result, high expression of *MYO1B* was an independent predictive factor for survival \[hazard ratio (HR), 1.68; 95% confidence interval (CI), 1.13--2.49; p=0.01\] ([Fig. 8](#f8-ijo-52-01-0166){ref-type="fig"}).

Downstream genes affected by silencing of MYO1B in SAS cells
------------------------------------------------------------

Finally, we performed genome-wide gene expression analysis using si-*MYO1B* in SAS cells to investigate which genes were mediated by *MYO1B* signaling. A SurePrint G3 Human GE 60K v3 microarray was used for genome-wide expression analysis. We submitted the raw data to the GEO database (accession no. GSE100746). In this study, we focused on significantly downregulated genes by both si-*MYO1B*-1 and si-*MYO1B*-2 transfection (log~2~ \[si-*MYO1B*/mock\] \<−1.5). *MYO1B* was the most significantly downregulated gene, indicating that the array data were worthy of evaluation. Genes significantly downregulated by silencing of *MYO1B* are listed in [Table III](#tIII-ijo-52-01-0166){ref-type="table"}. Among *MYO1B* downstream genes, expression of 5 genes (*ANXA10*, *TRIM9*, *TCTN3*, *BTBD16* and *CYP19A1*) was significantly associated with poor prognosis in patients with HNSCC based on TCGA database ([Fig. 9](#f9-ijo-52-01-0166){ref-type="fig"}).

Discussion
==========

Accumulating evidence has shown that aberrant expression of miRNAs disrupts the well-ordered RNA networks in cancer cells and is involved in the pathogenesis of human cancers ([@b22-ijo-52-01-0166]). Based on the miRNA expression signatures of human cancers, we have sequentially identified antitumor miRNAs that regulate novel cancer networks ([@b16-ijo-52-01-0166],[@b23-ijo-52-01-0166]--[@b26-ijo-52-01-0166]). Analyses of our miRNA signature of HNSCC by RNA sequencing showed that several passenger strands of miRNAs were significantly downregulated in cancer tissues ([@b8-ijo-52-01-0166]). Our recent study demonstrated that both strands of pre-*miR-150* (*miR-150-5p*, guide strand; and *miR-150-3p*, passenger strand) had antitumor functions and that these miRNAs cooperatively regulated oncogenic *ITGA3*, *ITGA6* and *TNC* in HNSCC cells ([@b8-ijo-52-01-0166]). Our other studies showed that the passenger strand of *miR-150* acted as an anti-tumor miRNA in several types of cancers, such as esophageal cancer and prostate cancer ([@b9-ijo-52-01-0166],[@b27-ijo-52-01-0166]). These findings suggested that miRNA passenger strands also contribute substantially to cancer pathogenesis and that identification of RNA networks mediated by miRNA passenger strands may provide novel insights into the pathogenesis of HNSCC.

Based on our miRNA signature of HNSCC, we focused on the passenger strand *miR-145-3p* in this study. Similarly, *miR-145-5p*, the guide strand of miR-145, was significantly reduced in this signature. Downregulation of *miR-145-5p* is frequently observed in many types of cancer, and prior studies have confirmed the antitumor function of *miR-145-5p* by demonstration of its effects on several types of oncogenes in cancer cells ([@b10-ijo-52-01-0166],[@b11-ijo-52-01-0166]). Several studies have shown that downregulation of *miR-145-5p* is caused by hypermethylation of the promoter region of pre-*miR-145* in prostate cancer ([@b28-ijo-52-01-0166]). Importantly, the tumor suppressor p53 has been shown to directly bind p53-response elements in the promoter region of pre-*miR-145* and to control the expression of *miR-145-5p* ([@b29-ijo-52-01-0166]). p53 mutations are found in \>50% of patients with HNSCC ([@b30-ijo-52-01-0166]). Thus, downregulation of *miR-145-5p* and *miR-145-3p* may be dependent on p53 inactivation in cancer cells.

Expression levels of passenger strand of *miR-145-3p* was lower than *miR-145-5p* as a guide strand miRNA in HNSCC clinical specimens and cell lines. Our previous studies of bladder, lung, and prostate cancers showed that expression levels of *miR-145-3p* was lower than *miR-145-5p* in each cancer ([@b10-ijo-52-01-0166],[@b11-ijo-52-01-0166],[@b31-ijo-52-01-0166]). The results of the present data of HNSCC was similar to our previous data. Explanation is incomplete as to in what kind of molecular mechanisms the expression of the two miRNAs differ. This problem is an important issue in miRNA biosynthesis.

Our functional assays showed that *miR-145-3p* had antitumor functions similar to *miR-145-5p* in HNSCC cells. We have also demonstrated *miR-145-3p* is downregulated in cancer tissues and acts as an antitumor miRNA in bladder, lung, and prostate cancers by targeting several oncogenic genes ([@b10-ijo-52-01-0166],[@b11-ijo-52-01-0166],[@b31-ijo-52-01-0166]). Previous studies demonstrated that several oncogenic genes were regulated by *miR-145-5p* in several types of cancers ([@b32-ijo-52-01-0166]--[@b34-ijo-52-01-0166]). There are few studies for target genes by *miR-145-3p* regulation in cancer cells, including HNSCC cells. Thus, we evaluated *miR-145-3p* regulatory oncogenic networks in HNSCC cells; a total of 14 putative targets of *miR-145-3p* in HNSCC cells were identified in this study. Among these candidates, *MYO1B*, *C16orf74*, *SP9* and *RBP1* were found to be associated with poor prognosis in patients with HNSCC by TCGA data analyses.

In this study, we focused on *MYO1B* because high expression of *MYO1B* was strongly associated with poor prognosis in patients with HNSCC. Myosins are actin-associated molecular motor proteins that regulate membrane tension, anchor membrane proteins and organelles, and transport inter-cellular vesicles ([@b35-ijo-52-01-0166],[@b36-ijo-52-01-0166]). We have demonstrated that antitumor miRNAs inhibited cancer cell migration and invasion through targeting several actin-binding proteins and actin-associate proteins, e.g., FSCN1, LASP1, ARPC5 and ANLN ([@b37-ijo-52-01-0166]--[@b40-ijo-52-01-0166]). Overexpression of these proteins has been detected in cancer tissues and has been shown to contribute to cancer cell aggressiveness.

Our present data of restoration of *miR-145-5p* or *miR-145-3p* showed the inhibition of cancer cell proliferation. However, inhibition of cell proliferation was weak by knockdown of *MYO1B* in HNSCC cells. These data suggest that *miR-145-5p* or *miR-145-3p* inhibite cell proliferation genes and pathways which do not rely on MYO1B in HNSCC cells.

MYO1B belongs to a member of the membrane-associated class I myosin family and functions as a linker between membranes and the actin cytoskeleton in several cellular processes ([@b41-ijo-52-01-0166]). Previous studies have demonstrated other functions of MYO1B. For example, MYO1B is localized in the endocytotic compartment and has pivotal roles in endocytosis ([@b42-ijo-52-01-0166]). MYO1B couples with the actin assembly to organelles and controls membrane remodeling at the trans-Golgi network ([@b43-ijo-52-01-0166]). In cancer cells, *MYO1B* is highly expressed in PC-3 metastatic prostate cancer cells, and knockdown of *MYO1B* affects the cytoskeleton and cell migration ([@b44-ijo-52-01-0166]). Another study showed that knockdown of *MYO1B* significantly inhibits migratory and invasive abilities of HNSCC cells *in vitro* and *in vivo* ([@b35-ijo-52-01-0166]). Our present data confirmed these findings and suggested that MYO1B may be an effective target for the treatment of HNSCC.

To identify MYO1B-mediated HNSCC pathways, we performed genome-wide gene expression analyses using si-*MYO1B* transfectants. A total of 54 genes were found to be mediated by MYO1B in HNSCC. Among them, 5 genes (*ANXA10*, *TRIM9*, *TCTN3*, *BTBD16* and *CYP19A1*) were significantly associated with poor prognosis in patients with HNSCC by TCGA database analyses. Annexin family proteins are calcium-dependent phospholipid-binding proteins that regulate cell growth and signal transduction ([@b45-ijo-52-01-0166]). Overexpression of *ANXA10* has been reported in oral squamous cell carcinoma, and expression of *ANXA10* promotes cancer cell proliferation through regulating mitogen-activated protein kinase signaling pathways ([@b46-ijo-52-01-0166]). Exploration of novel *MYO1B*-mediated pathways may improve our understanding of the aggressiveness of this disease.

In conclusion, downregulation of *miR-145-3p* was observed in HNSCC clinical specimens, and this passenger strand acted as an antitumor miRNA through targeting *MYO1B* in HNSCC cells. *MYO1B* was highly expressed in HNSCC clinical specimens and was found to promote cancer aggressiveness in functional assays. Elucidation of the pathways mediated by the *miR-145-3p*/*MYO1B* axis is expected to contribute to further analyses of oncogenesis mechanisms and treatment strategies in HNSCC.
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![Antitumor function of *miR-145-5p* and *miR-145-3p* in head and neck squamous cell carcinoma (HNSCC) cells. (A) Expression levels of *miR-145-5p* and *miR-145-3p* in HNSCC clinical specimens and cell lines. *RNU48* was used as an internal control. Spearman\'s rank test showed a positive correlation between the expression of *miR-145-5p* and *miR-145-3p*. ^\*^p\<0.0001. (B) Cell proliferation was determined by XTT assays 72 h after transfection with *miR-145-5p* and *miR-145-3p*. ^\*^p\<0.0001. (C) Cell migration activity was determined using migration assays. ^\*^p\<0.0001. (D) Cell invasion activity was determined using Matrigel invasion assays. ^\*^p\<0.0001.](IJO-52-01-0166-g00){#f1-ijo-52-01-0166}

![Both strands of *miR-145-5p* and *miR-145-3p* were incorporated into the RISC. (A and B) Expression levels of *miR-145-5p* and *miR-145-3p* after transfection with *miR-145-5p* or *miR-145-3p* following immunoprecipitation by Ago2 (^\*^p\<0.0001).](IJO-52-01-0166-g01){#f2-ijo-52-01-0166}

![Flow chart illustrating the analysis strategy for *miR-145-3p* targets in head and neck squamous cell carcinoma (HNSCC) cells. A total of 3,164 genes were putative target genes of *miR-145-3p* in TargetScan database analysis (release 7.1). Finally, 14 genes were selected as putative targets of *miR-145-3p* in HNSCC cells.](IJO-52-01-0166-g02){#f3-ijo-52-01-0166}

![The Cancer Genome Atlas (TCGA) database analysis of putative targets of *miR-145-3p* in head and neck squamous cell carcinoma (HNSCC). Kaplan-Meier plots of overall survival with log-rank tests for 14 genes with high and low expression in the HNSCC TCGA database.](IJO-52-01-0166-g03){#f4-ijo-52-01-0166}

![Regulation of myosin 1B (*MYO1B*) expression by *miR-145-3p* in head and neck squamous cell carcinoma (HNSCC) cells. (A) Expression levels of *MYO1B* mRNA 48 h after transfection with 10 nM *miR-145-5p* or *miR-145-3p* into cell lines. *GUSB* was used as an internal control. ^\*^p\<0.0001. (B) Protein expression of *MYO1B* 72 h after transfection with *miR-145-5p* or *miR-145-3p*. GAPDH was used as a loading control. (C) *miR-145-3p* binding sites in the 3′-untranslated region (3′-UTR) of *MYO1B* mRNA. (D) Dual luciferase reporter assays using vectors encoding putative *miR-145-3p* target sites (positions 88--94 or 1117--1123) in the *MYO1B* 3′-UTR for both wild-type and deleted regions. Normalized data were calculated as the ratio of *Renilla*/Firefly luciferase activities. ^\*^p\<0.0001.](IJO-52-01-0166-g04){#f5-ijo-52-01-0166}

![Effects of myosin 1B (*MYO1B*) silencing in head and neck squamous cell carcinoma (HNSCC) cell lines. (A) *MYO1B* mRNA expression 72 h after transfection with 10 nM si-*MYO1B* into HNSCC cell lines. *GUSB* was used as an internal control. ^\*^p\<0.0001. (B) Protein expression 72 h after transfection with si-MYO1B. GAPDH was used as a loading control. (C) Cell proliferation was determined with XTT assays 72 h after transfection with 10 nM si-*MYO1B*-1 or si-*MYO1B*-2. ^\*^p\<0.0001. (D) Cell migration activity was determined by migration assays. ^\*^p\<0.0001. (E) Cell invasion activity was determined using Matrigel invasion assays. ^\*^p\<0.0001.](IJO-52-01-0166-g05){#f6-ijo-52-01-0166}

![Expression of myosin 1B (*MYO1B*) in clinical specimens of head and neck squamous cell carcinoma (HNSCC). (A) Expression levels of *MYO1B* in HNSCC clinical specimens. *GUSB* was used as an internal control. ^\*^p\<0.0001. (B) The negative correlation between MYO1B expression and *miR-145-3p* (r=−0.461 and p=0.0025). Spearman\'s rank test was used to evaluate the correlation. (C) Immunostaining showed that MYO1B was strongly expressed in cancer lesions (×100 and ×400 magnification field).](IJO-52-01-0166-g06){#f7-ijo-52-01-0166}

![Multivariate Cox proportional hazard regression models for overall survival. Multivariate Cox proportional hazards model for prediction of overall survival showed that high myosin 1B (*MYO1B*) expression, cT stage, cN stage, and age were significant prognostic factors (p= 0.01, p= 0.01, p\<0.0001 and p=0.03, respectively).](IJO-52-01-0166-g07){#f8-ijo-52-01-0166}

![The Cancer Genome Atlas (TCGA) database analysis of myosin 1B (*MYO1B*) downstream genes. Kaplan-Meier survival curve for overall survival with log-rank tests for 5 *MYO1B* downstream genes with high or low expression. TCGA dataset for head and neck squamous cell carcinoma (HNSCC) was analyzed.](IJO-52-01-0166-g08){#f9-ijo-52-01-0166}

###### 

Clinical features of 22 patients with HNSCC.

  No.   Age   Sex   Location     T    N    M   Stage   Differentiation
  ----- ----- ----- ------------ ---- ---- --- ------- ------------------
  1     64    F     Oral floor   4a   2c   0   IVA     Moderate
  2     73    M     Tongue       3    2b   0   IVA     Poor
  3     77    M     Tongue       2    2b   0   IVA     Poor
  4     63    F     Oral floor   2    2b   0   IVA     Basaloid SCC
  5     59    M     Tongue       1    2a   0   IVA     Moderate
  6     36    F     Tongue       3    1    0   III     Moderate
  7     67    M     Tongue       3    0    0   III     Moderate
  8     60    F     Tongue       2    1    0   III     Well
  9     66    M     Tongue       2    0    0   II      Moderate
  10    67    M     Tongue       2    0    0   II      Poor to moderate
  11    76    F     Tongue       1    0    0   I       Well
  12    69    M     Tongue       1    0    0   I       Well
  13    73    F     Tongue       1    0    0   I       Well
  14    64    M     Tongue       1    0    0   I       Well
  15    70    M     Tongue       1    0    0   I       Well
  16    38    M     Tongue       1    0    0   I       Well
  17    51    M     Tongue       1    0    0   I       Well
  18    34    F     Tongue       1    0    0   I       Poor
  19    70    M     Tongue       1    0    0   I       Moderate
  20    71    M     Tongue       1    0    0   I       Well
  21    82    M     Oral floor   1    0    0   I       Well
  22    81    M     Tongue       1    0    0   I       Extremely well

HNSCC, head and neck squamous cell carcinoma; F, female; M, male; TNM classification and tumor stage were determined by the union for International Cancer Control (UICC).

###### 

Putative targets of *miR-145-3p* regulation in HNSCC cells.

  Gene symbol   Gene name                                                Conserved site count   SAS *miR-145-3p* transfection   HNSCC fold-change   Prognosis (high vs. low) p-value
  ------------- -------------------------------------------------------- ---------------------- ------------------------------- ------------------- ------------------------------------------------------
  MYO1B         Myosin IB                                                2                      −1.49                           1.72                0.00452
  C16orf74      Chromosome 16 open reading frame 74                      1                      −0.88                           1.97                0.014
  SP9           Sp9 transcription factor                                 1                      −0.97                           2.38                0.0277[a](#tfn3-ijo-52-01-0166){ref-type="table-fn"}
  RBP1          Retinol binding protein 1, cellular                      1                      −1.2                            2.6                 0.0316
  LRRC3         Leucine rich repeat containing 3                         2                      −0.86                           1.54                0.0749
  PSPH          Phosphoserine phosphatase                                1                      −0.8                            1.95                0.0804
  CDCA7L        Cell division cycle associated 7-like                    1                      −0.88                           1.71                0.107
  CBS           Cystathionine-β-synthase                                 2                      −1.29                           1.54                0.228
  SH2D5         SH2 domain containing 5                                  1                      −1.87                           2.34                0.301
  PXDN          Peroxidasin homolog (*Drosophila*)                       1                      −0.94                           1.63                0.317
  CYP27B1       Cytochrome P450, family 27, subfamily B, polypeptide 1   2                      −0.86                           2.65                0.531
  TNK2          Tyrosine kinase, non-receptor, 2                         1                      −1.08                           2.3                 0.789
  ALDH1L2       Aldehyde dehydrogenase 1 family, member L2               1                      −1.19                           2.3                 0.855
  CCDC103       Coiled-coil domain containing 103                        1                      −1.77                           2.03                0.986

HNSCC, head and neck squamous cell carcinoma;

poor prognosis with low expression.

###### 

Identification of *MYO1B* downstream genes in HNSCC cells.

  Gene symbol   Gene name                                                         Log~2~ (si-*MYO1B*-1/mock)   Log~2~ (si-*MYO1B*-2/mock)   Average Log~2~ (si-*MYO1B*/mock)
  ------------- ----------------------------------------------------------------- ---------------------------- ---------------------------- ----------------------------------
  MYO1B         Myosin IB                                                         −4.007414                    −4.668526                    −4.337970
  ANXA10        Annexin A10                                                       −3.842131                    −2.8575826                   −3.349857
  MATN3         Matrilin 3                                                        −4.224010                    −2.0824907                   −3.153250
  SOHLH1        Spermatogenesis and oogenesis specific basic helix-loop-helix 1   −4.337910                    −1.8513346                   −3.094622
  SMAD1-AS1     SMAD1 antisense RNA 1                                             −3.191749                    −2.902154                    −3.046952
  KRT6B         Keratin 6B, type II                                               −3.626921                    −2.0426638                   −2.834793
  KLK13         Kallikrein-related peptidase 13                                   −3.540325                    −1.9546604                   −2.747493
  PAX6          Paired box 6                                                      −2.130839                    −3.0853565                   −2.608098
  C5orf66-AS1   C5orf66 antisense RNA 1                                           −2.704701                    −2.1148643                   −2.409783
  PDGFRB        Platelet-derived growth factor receptor, β polypeptide            −2.886416                    −1.8465691                   −2.366492
  HSD17B2       Hydroxysteroid (17-β) dehydrogenase 2                             −2.325892                    −2.3811436                   −2.353518
  SP140         SP140 nuclear body protein                                        −2.470807                    −2.1072135                   −2.289010
  OR9G4         Olfactory receptor, family 9, subfamily G, member 4               −2.296291                    −2.1278794                   −2.212085
  FOXD3-AS1     FOXD3 antisense RNA 1 (head to head)                              −1.846461                    −2.4128325                   −2.129647
  MAGEB17       Melanoma antigen family B, 17                                     −2.394958                    −1.7456088                   −2.070283
  AMDHD1        Amidohydrolase domain containing 1                                −2.223687                    −1.916799                    −2.070243
  IGFBP1        Insulin-like growth factor binding protein 1                      −2.512259                    −1.5926342                   −2.052446
  MMP1          Matrix metallopeptidase 1 (interstitial collagenase)              −1.821691                    −2.2728753                   −2.047283
  EN1           Engrailed homeobox 1                                              −1.834606                    −2.220468                    −2.027537
  FGF13-AS1     FGF13 antisense RNA 1                                             −2.349053                    −1.6906263                   −2.019840
  ZC3H12D       Zinc finger CCCH-type containing 12D                              −2.232335                    −1.8071643                   −2.019749
  KRT6A         Keratin 6A, type II                                               −2.307169                    −1.6317264                   −1.969448
  FAM196B       Family with sequence similarity 196, member B                     −1.855253                    −2.031945                    −1.943599
  DNMT3B        DNA (cytosine-5-)-methyltransferase 3β                            −1.530055                    −2.3343146                   −1.932185
  LIN28A        Lin-28 homolog A (*C. elegans*)                                   −2.292716                    −1.5482489                   −1.920483
  ZNF501        Zinc finger protein 501                                           −1.788270                    −2.042201                    −1.915235
  REC114        REC114 meiotic recombination protein                              −2.230243                    −1.5574937                   −1.893868
  TRIM9         Tripartite motif containing 9                                     −2.078308                    −1.691343                    −1.884826
  ZBED3-AS1     ZBED3 antisense RNA 1                                             −2.140241                    −1.6105609                   −1.875401
  PHKA2-AS1     PHKA2 antisense RNA 1                                             −2.028810                    −1.7067645                   −1.867787
  ZDHHC22       Zinc finger, DHHC-type containing 22                              −2.044774                    −1.6702744                   −1.857524
  SCAND2P       SCAN domain containing 2 pseudogene                               −1.924617                    −1.7586662                   −1.841642
  SPRR1B        Small proline-rich protein 1B                                     −1.967544                    −1.7028618                   −1.835203
  SLC35D3       Solute carrier family 35, member D3                               −1.638228                    −2.0054185                   −1.821823
  ANO1-AS2      ANO1 antisense RNA 2 (head to head)                               −1.763001                    −1.8544457                   −1.808723
  C22orf23      Chromosome 22 open reading frame 23                               −1.741993                    −1.8479792                   −1.794986
  TCTN3         Tectonic family member 3                                          −1.880425                    −1.6976513                   −1.789038
  FAM198A       Family with sequence similarity 198, member A                     −1.940336                    −1.6032256                   −1.771781
  TG            Thyroglobulin                                                     −1.719962                    −1.8222181                   −1.771090
  RASGEF1A      RasGEF domain family, member 1A                                   −1.865154                    −1.6762245                   −1.770689
  KATNAL2       Katanin p60 subunit A-like 2                                      −1.982902                    −1.5259477                   −1.754425
  KLHL14        Kelch-like family member 14                                       −1.575037                    −1.9020982                   −1.738568
  NANOS1        Nanos homolog 1 (*Drosophila*)                                    −1.785024                    −1.6778822                   −1.731453
  BTBD16        BTB (POZ) domain containing 16                                    −1.769118                    −1.6703396                   −1.719729
  APOL4         Apolipoprotein L, 4                                               −1.542360                    −1.8804932                   −1.711427
  ZNF385C       Zinc finger protein 385C                                          −1.792121                    −1.6219425                   −1.707032
  ABO           ABO blood group                                                   −1.624970                    −1.7806495                   −1.702810
  CD200R1       CD200 receptor 1                                                  −1.778945                    −1.5290467                   −1.653996
  VWA3A         Von Willebrand factor A domain containing 3A                      −1.527752                    −1.7406074                   −1.634180
  CYP19A1       Cytochrome P450, family 19, subfamily A, polypeptide 1            −1.572258                    −1.6706244                   −1.621441
  ZNF880        Zinc finger protein 880                                           −1.604488                    −1.6321578                   −1.618323
  NKX6-2        NK6 homeobox 2                                                    −1.597461                    −1.6252115                   −1.611336
  GPR157        G protein-coupled receptor 157                                    −1.583724                    −1.6133837                   −1.598554
  ST3GAL5-AS1   ST3GAL5 antisense RNA 1 (head to head)                            −1.526179                    −1.5542628                   −1.540221
